RxDoctor Payments Data

Maggie Jones

Physician Assistant · Lillington, NCNPI 1053903401

Payments from drug & device makers

$2,348in general payments, 2019–2025

Across 144 payments — averaging $16.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$719
  • Lilly USA, LLC$191
  • AstraZeneca$185
  • Sanofi-aventis U.S. LLC$145
  • AbbVie$139
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$132
  • plus $837 from 19 others

What the payments were for

  • Food & beverage$2,348100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,348 in reported general payments places this provider in the 80th percentile of 7,441 physician assistant providers in North Carolina.

See all physician assistant providers in North Carolina

Medicare billing

Part B allowed, 2024
$38,191
Medicare patients
55
Services billed
466

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban175$114,894
MyrbetriqMirabegron81$42,145
Trelegy ElliptaFluticasone/Umeclidin/Vilanter41$32,488
XareltoRivaroxaban37$24,812
JardianceEmpagliflozin42$22,136
FarxigaDapagliflozin Propanediol23$14,573
OzempicSemaglutide13$12,107
TradjentaLinagliptin19$10,374
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$7,167
Omeprazole190$3,682
Olanzapine OdtOlanzapine26$3,628
Duloxetine Hcl90$3,612
Gabapentin181$3,382
Lantus SolostarInsulin Glargine,hum.Rec.Anlog46$2,999
LumiganBimatoprost12$2,960

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$32$114,894175 claims
Boehringer IngelheimJardiance, Tradjenta$77$32,51061 claims
GSKTrelegy Ellipta$49$32,48841 claims
AstraZenecaFarxiga, Breztri Aerosphere$185$21,74034 claims
Novo NordiskOzempic$719$12,10713 claims
AbbVieLumigan$139$2,96012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,441 physician assistant providers in North Carolina.

Other physician assistant in Lillington

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →